MaxCyte, Inc. Director Dealings (3554T)
March 19 2019 - 1:05PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3554T
MaxCyte, Inc.
19 March 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Issue of Equity
Gaithersburg, Maryland - 19 March 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based medicines and life sciences company,
announces that J. Stark Thompson, Non-Executive Chairman of the
Company, has exercised options over 25,000 shares of common stock
of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order
to fund a near term personal tax liability, the 25,000 new shares
of Common Stock issued pursuant to the Exercise ("New Common
Stock") have today been sold by Dr Thompson at a price of 180 pence
per Common Stock ("Sale"). Dr Thompson has no current intention of
making further sales of MaxCyte shares.
Following the Exercise and Sale, Dr Thompson's holding of Common
Stock remains unchanged at a total of 110,918 Common Stock
representing a total of 0.2% of the issued share capital of the
Company. Dr Thompson holders a further 239,533 options over Common
Stock.
Total voting rights
The New Common Stock will be allocated out of the common stock
the subject of the block listing announced on 2 May 2017. The New
Common Stock will rank pari passu with the existing shares of
common stock of the Company. The total issued stock capital of the
Company following the above will be 57,316,500 shares of common
stock. Shareholders in the Company may use this figure as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 51,357,764 and the number of restricted shares
of Common Stock trading under the symbol 'MXCS' is 5,958,736.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name J. Stark Thompson
=============================== =============================================
2 Reason for the notification
==============================================================================
a) Position/status Non-Executive Chairman and PDMR
=============================== =============================================
b) Initial notification/Amendment Initial notification
=============================== =============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==============================================================================
a) Name MaxCyte, Inc.
=============================== =============================================
b) LEI 54930053YHXULRFCU991
=============================== =============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
==============================================================================
a) Description of Exercise of options and Sale of Common
the financial Stock
instrument, type
of instrument
=============================== =============================================
b) Identification US57777K1060
Code
=============================== =============================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
=============================== =============================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== =================== ========================
N/A 25,000 (option exercise)
180.00 pence 25,000 (sale of common
stock)
=============================== =================== ========================
e) Aggregated information N/A
- Aggregated volume 25,000
- Price 180.00 (sale of common stock)
=============================== =============================================
f) Date of the transaction 19 March 2019
=============================== =============================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== =============================================
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its core business, MaxCyte
leverages its Flow Electroporation(R) Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies, has more than 70 partnered
program licenses in cell therapy including more than 35 licensed
for clinical use. With its robust delivery technology platform,
MaxCyte helps its partners to unlock the full potential of their
products. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHJLMFTMBABBLL
(END) Dow Jones Newswires
March 19, 2019 13:05 ET (17:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024